MedTrace Logo

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

NCT03115619 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2020-08-21

No results posted yet for this study

Summary

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

Conditions

Interventions

DRUG

Pirfenidone

Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-18
Primary Completion
2020-01-10
Completion
2020-01-10
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03115619 on ClinicalTrials.gov